Rocket Pharmaceuticals (RCKT) PT Lowered to $32 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JPMorgan Downgrades Rocket Pharmaceuticals (RCKT) to Neutral
May 28, 2025 3:07 PM EDTJPMorgan analyst Eric Joseph downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Overweight to Neutral with a price target of $7.00 (from $44.00).
The analyst comments "We are downgrading RCKT shares to Neutral from Overweight on the back of yesterdays announced clinical hold on lead program RP-A501... More
Goldman Sachs Downgrades Rocket Pharmaceuticals (RCKT) to Sell
May 28, 2025 9:35 AM EDTGoldman Sachs analyst Richard Law downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Buy to Sell with a price target of $2.00 (from $13.00).
The analyst comments "On Tuesday (5/27), RCKT announced that the FDA placed a clinical hold on its pivotal Ph. 2 Danon disease (DD) trial. The hold was issued on 5/23 after a patient treated in early May experienced capillary... More
Rocket Pharmaceuticals (RCKT) PT Lowered to $9 at BofA Securities
May 28, 2025 5:13 AM EDTBofA Securities analyst Greg Harrison lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $9.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Rockets announcement of a death in its RP-A501 phase 2 for rare disorder Danon is tragic on... More
William Blair Reiterates Outperform Rating on Rocket Pharmaceuticals (RCKT)
May 27, 2025 10:49 AM EDTWilliam Blair analyst Sami Corwin reiterated an Outperform rating on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Stock Thoughts: We view the patient death and subsequent clinical hold as unfortunate; however, we believe the pausing of dosing is necessary given CLS is a safety event not previously observed with RP-A501 or other AAV gene therapies, to our knowledge. While we cannot fully eliminate the possibility that... More
BMO Capital on Rocket Pharmaceuticals (RCKT): 'we expect today's announcement...to significantly pressure RCKT'
May 27, 2025 8:10 AM EDTBMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $30.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Mgt announced a patient death in Danon trial following capillary leak syndrome sAE, triggering a clinical hold by the FDA. Importantly, the event... More
Jefferies on Rocket Pharmaceuticals (RCKT): 'We expect significant stock weakness'
May 27, 2025 8:07 AM EDTJefferies analyst Andrew Tsai reiterated a Buy rating and $29.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "We expect significant stock weakness as a Danon patient died due to an acute systemic infection (following an SAE), leading the... More
